Perspectives for therapeutic HPV vaccine development

Andrew Yang, Emily Farmer, Tzyy Choou Wu, Chien-Fu Hung

Research output: Contribution to journalArticle

Abstract

Background: Human papillomavirus (HPV) infections and associated diseases remain a serious burden worldwide. It is now clear that HPV serves as the etiological factor and biologic carcinogen for HPV-associated lesions and cancers. Although preventative HPV vaccines are available, these vaccines do not induce strong therapeutic effects against established HPV infections and lesions. These concerns create a critical need for the development of therapeutic strategies, such as vaccines, to treat these existing infections and diseases. Main Body: Unlike preventative vaccines, therapeutic vaccines aim to generate cell-mediated immunity. HPV oncoproteins E6 and E7 are responsible for the malignant progression of HPV-associated diseases and are consistently expressed in HPV-associated diseases and cancer lesions; therefore, they serve as ideal targets for the development of therapeutic HPV vaccines. In this review we revisit therapeutic HPV vaccines that utilize this knowledge to treat HPV-associated lesions and cancers, with a focus on the findings of recent therapeutic HPV vaccine clinical trials. Conclusion: Great progress has been made to develop and improve novel therapeutic HPV vaccines to treat existing HPV infections and diseases; however, there is still much work to be done. We believe that therapeutic HPV vaccines have the potential to become a widely available and successful therapy to treat HPV and HPV-associated diseases in the near future.

Original languageEnglish (US)
Pages (from-to)1-19
Number of pages19
JournalJournal of Biomedical Science
Volume23
Issue number1
DOIs
StatePublished - Nov 4 2016

Fingerprint

Papillomavirus Vaccines
Vaccines
Papillomavirus Infections
Therapeutics
Oncogene Proteins
Biological Factors
Carcinogens
Neoplasms
Therapeutic Uses
Cellular Immunity
Clinical Trials

Keywords

  • Cervical cancer
  • HPV
  • HPV E6
  • HPV E7
  • Human papillomavirus
  • Therapeutic vaccine

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Perspectives for therapeutic HPV vaccine development. / Yang, Andrew; Farmer, Emily; Wu, Tzyy Choou; Hung, Chien-Fu.

In: Journal of Biomedical Science, Vol. 23, No. 1, 04.11.2016, p. 1-19.

Research output: Contribution to journalArticle

@article{f93c9ef8569a442eac1be313b9c30113,
title = "Perspectives for therapeutic HPV vaccine development",
abstract = "Background: Human papillomavirus (HPV) infections and associated diseases remain a serious burden worldwide. It is now clear that HPV serves as the etiological factor and biologic carcinogen for HPV-associated lesions and cancers. Although preventative HPV vaccines are available, these vaccines do not induce strong therapeutic effects against established HPV infections and lesions. These concerns create a critical need for the development of therapeutic strategies, such as vaccines, to treat these existing infections and diseases. Main Body: Unlike preventative vaccines, therapeutic vaccines aim to generate cell-mediated immunity. HPV oncoproteins E6 and E7 are responsible for the malignant progression of HPV-associated diseases and are consistently expressed in HPV-associated diseases and cancer lesions; therefore, they serve as ideal targets for the development of therapeutic HPV vaccines. In this review we revisit therapeutic HPV vaccines that utilize this knowledge to treat HPV-associated lesions and cancers, with a focus on the findings of recent therapeutic HPV vaccine clinical trials. Conclusion: Great progress has been made to develop and improve novel therapeutic HPV vaccines to treat existing HPV infections and diseases; however, there is still much work to be done. We believe that therapeutic HPV vaccines have the potential to become a widely available and successful therapy to treat HPV and HPV-associated diseases in the near future.",
keywords = "Cervical cancer, HPV, HPV E6, HPV E7, Human papillomavirus, Therapeutic vaccine",
author = "Andrew Yang and Emily Farmer and Wu, {Tzyy Choou} and Chien-Fu Hung",
year = "2016",
month = "11",
day = "4",
doi = "10.1186/s12929-016-0293-9",
language = "English (US)",
volume = "23",
pages = "1--19",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Perspectives for therapeutic HPV vaccine development

AU - Yang, Andrew

AU - Farmer, Emily

AU - Wu, Tzyy Choou

AU - Hung, Chien-Fu

PY - 2016/11/4

Y1 - 2016/11/4

N2 - Background: Human papillomavirus (HPV) infections and associated diseases remain a serious burden worldwide. It is now clear that HPV serves as the etiological factor and biologic carcinogen for HPV-associated lesions and cancers. Although preventative HPV vaccines are available, these vaccines do not induce strong therapeutic effects against established HPV infections and lesions. These concerns create a critical need for the development of therapeutic strategies, such as vaccines, to treat these existing infections and diseases. Main Body: Unlike preventative vaccines, therapeutic vaccines aim to generate cell-mediated immunity. HPV oncoproteins E6 and E7 are responsible for the malignant progression of HPV-associated diseases and are consistently expressed in HPV-associated diseases and cancer lesions; therefore, they serve as ideal targets for the development of therapeutic HPV vaccines. In this review we revisit therapeutic HPV vaccines that utilize this knowledge to treat HPV-associated lesions and cancers, with a focus on the findings of recent therapeutic HPV vaccine clinical trials. Conclusion: Great progress has been made to develop and improve novel therapeutic HPV vaccines to treat existing HPV infections and diseases; however, there is still much work to be done. We believe that therapeutic HPV vaccines have the potential to become a widely available and successful therapy to treat HPV and HPV-associated diseases in the near future.

AB - Background: Human papillomavirus (HPV) infections and associated diseases remain a serious burden worldwide. It is now clear that HPV serves as the etiological factor and biologic carcinogen for HPV-associated lesions and cancers. Although preventative HPV vaccines are available, these vaccines do not induce strong therapeutic effects against established HPV infections and lesions. These concerns create a critical need for the development of therapeutic strategies, such as vaccines, to treat these existing infections and diseases. Main Body: Unlike preventative vaccines, therapeutic vaccines aim to generate cell-mediated immunity. HPV oncoproteins E6 and E7 are responsible for the malignant progression of HPV-associated diseases and are consistently expressed in HPV-associated diseases and cancer lesions; therefore, they serve as ideal targets for the development of therapeutic HPV vaccines. In this review we revisit therapeutic HPV vaccines that utilize this knowledge to treat HPV-associated lesions and cancers, with a focus on the findings of recent therapeutic HPV vaccine clinical trials. Conclusion: Great progress has been made to develop and improve novel therapeutic HPV vaccines to treat existing HPV infections and diseases; however, there is still much work to be done. We believe that therapeutic HPV vaccines have the potential to become a widely available and successful therapy to treat HPV and HPV-associated diseases in the near future.

KW - Cervical cancer

KW - HPV

KW - HPV E6

KW - HPV E7

KW - Human papillomavirus

KW - Therapeutic vaccine

UR - http://www.scopus.com/inward/record.url?scp=84994032253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994032253&partnerID=8YFLogxK

U2 - 10.1186/s12929-016-0293-9

DO - 10.1186/s12929-016-0293-9

M3 - Article

VL - 23

SP - 1

EP - 19

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

ER -